Short Interest in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Declines By 50.0%

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the recipient of a significant drop in short interest in July. As of July 15th, there was short interest totaling 22,521 shares, a drop of 50.0% from the June 30th total of 45,019 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average trading volume of 33,926 shares, the days-to-cover ratio is presently 0.7 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, July 10th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

China SXT Pharmaceuticals Stock Down 20.8%

China SXT Pharmaceuticals stock opened at $0.06 on Tuesday. China SXT Pharmaceuticals has a 1-year low of $0.05 and a 1-year high of $1,046.98. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.76 and a current ratio of 7.94. The stock’s fifty day moving average is $2.00 and its two-hundred day moving average is $6.82.

China SXT Pharmaceuticals (NASDAQ:SXTC) last announced its quarterly earnings results on Wednesday, July 1st. The company reported ($0.07) earnings per share (EPS) for the quarter. The business had revenue of $0.26 million during the quarter.

Institutional Investors Weigh In On China SXT Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new position in China SXT Pharmaceuticals in the fourth quarter valued at approximately $36,000. Virtu Financial LLC raised its holdings in China SXT Pharmaceuticals by 107.5% during the third quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after purchasing an additional 15,013 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of China SXT Pharmaceuticals during the 3rd quarter worth approximately $78,000. Hedge funds and other institutional investors own 5.02% of the company’s stock.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.